Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?

Melilli E, Manonelles A, Montero N, Grinyo J, Martinez-Castelao A, Bestard O, Cruzado J.

Clin Kidney J. 2018 Jun;11(3):413-421. doi: 10.1093/ckj/sfx120. Epub 2017 Nov 23.

2.

Long-term changes in the planktonic cnidarian community in a mesoscale area of the NW Mediterranean.

Guerrero E, Gili JM, Grinyó J, Raya V, Sabatés A.

PLoS One. 2018 May 1;13(5):e0196431. doi: 10.1371/journal.pone.0196431. eCollection 2018.

3.

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP.

Am J Transplant. 2017 Dec;17(12):3219-3227. doi: 10.1111/ajt.14452. Epub 2017 Sep 5.

4.

Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation.

Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M.

Transplantation. 2017 Feb;101 Suppl 2S:S1-S41. doi: 10.1097/TP.0000000000001563. No abstract available.

PMID:
28125449
5.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP.

N Engl J Med. 2016 Jan 28;374(4):333-43. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med. 2016 Feb 18;374(7):698.

6.

Investigating The Health-Economic Impact Of Biomarker-Driven Immunosuppression (Biodrim) Following Renal Transplantation.

Weber SA, Pietzsch M, Bestard O, Reinke P, Grinyo J.

Value Health. 2015 Nov;18(7):A534. doi: 10.1016/j.jval.2015.09.1669. Epub 2015 Oct 20. No abstract available.

7.

Chronic Kidney Disease is associated with an increase of Intimal Dendritic cells in a comparative autopsy study.

Hueso M, Torras J, Carrera M, Vidal A, Navarro E, Grinyó J.

J Inflamm (Lond). 2015 Mar 29;12:26. doi: 10.1186/s12950-015-0073-4. eCollection 2015.

8.

Differential impact of belatacept and cyclosporine A on central aortic blood pressure and arterial stiffness after renal transplantation.

Seibert FS, Steltzer J, Melilli E, Grannas G, Pagonas N, Bauer F, Zidek W, Grinyó J, Westhoff TH.

Clin Transplant. 2014 Sep;28(9):1004-9. doi: 10.1111/ctr.12413. Epub 2014 Jul 23.

PMID:
24974984
9.

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S.

Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459. Epub 2013 Sep 18.

10.

Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.

Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondragón-Ramirez GA, Kothari J, Pupim L, Larsen CP.

Am J Transplant. 2013 Nov;13(11):2875-83. doi: 10.1111/ajt.12460. Epub 2013 Sep 18.

11.

Detrimental effects of ocean acidification on the economically important Mediterranean red coral (Corallium rubrum).

Bramanti L, Movilla J, Guron M, Calvo E, Gori A, Dominguez-Carrió C, Grinyó J, Lopez-Sanz A, Martinez-Quintana A, Pelejero C, Ziveri P, Rossi S.

Glob Chang Biol. 2013 Jun;19(6):1897-908. doi: 10.1111/gcb.12171. Epub 2013 Apr 3.

PMID:
23505003
12.

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.

Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, Rial Mdel C, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N.

Transpl Int. 2012 Oct;25(10):1059-64. doi: 10.1111/j.1432-2277.2012.01535.x. Epub 2012 Jul 21.

13.

Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model.

Kurdián M, Herrero-Fresneda I, Lloberas N, Gimenez-Bonafe P, Coria V, Grande MT, Boggia J, Malacrida L, Torras J, Arévalo MA, González-Martínez F, López-Novoa JM, Grinyó J, Noboa O.

PLoS One. 2012;7(3):e32516. doi: 10.1371/journal.pone.0032516. Epub 2012 Mar 12.

14.

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.

Flechner SM, Glyda M, Cockfield S, Grinyó J, Legendre Ch, Russ G, Steinberg S, Wissing KM, Tai SS.

Am J Transplant. 2011 Aug;11(8):1633-44. doi: 10.1111/j.1600-6143.2011.03573.x. Epub 2011 Jun 10. Erratum in: Am J Transplant. 2012 Jan;12(1):268.

15.

Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting.

Le Meur Y, Borrows R, Pescovitz MD, Budde K, Grinyo J, Bloom R, Gaston R, Walker RG, Kuypers D, van Gelder T, Kiberd B.

Transplant Rev (Orlando). 2011 Apr;25(2):58-64. doi: 10.1016/j.trre.2011.01.002. Epub 2011 Mar 30. No abstract available.

PMID:
21454067
16.

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).

Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F.

Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb.

PMID:
21372756
17.

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.

Ferguson R, Grinyó J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, Marks WH, Agarwal M, Wu D, Dong Y, Garg P.

Am J Transplant. 2011 Jan;11(1):66-76. doi: 10.1111/j.1600-6143.2010.03338.x. Epub 2010 Nov 29.

18.

An integrated safety profile analysis of belatacept in kidney transplant recipients.

Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP.

Transplantation. 2010 Dec 27;90(12):1521-7. doi: 10.1097/TP.0b013e3182007b95.

PMID:
21088650
19.

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.

Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B.

Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd.

PMID:
21076381
20.

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J.

Clin J Am Soc Nephrol. 2011 Feb;6(2):430-9. doi: 10.2215/CJN.05840710. Epub 2010 Nov 4.

Supplemental Content

Loading ...
Support Center